Epigenetic re-expression of HIF-2α suppresses soft tissue sarcoma growth

61Citations
Citations of this article
63Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

In soft tissue sarcomas (STS), low intratumoural O2 (hypoxia) is a poor prognostic indicator. HIF-1α mediates key transcriptional responses to hypoxia, and promotes STS metastasis; however, the role of the related HIF-2α protein is unknown. Surprisingly, here we show that HIF-2α inhibits high-grade STS cell growth in vivo, as loss of HIF-2α promotes sarcoma proliferation and increases calcium and mTORC1 signalling in undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma. We find that most human STS have lower levels of EPAS1 (the gene encoding HIF-2α) expression relative to normal tissue. Many cancers, including STS, contain altered epigenetics, and our findings define an epigenetic mechanism whereby EPAS1 is silenced during sarcoma progression. The clinically approved HDAC inhibitor Vorinostat specifically increases HIF-2α, but not HIF-1α, accumulation in multiple STS subtypes. Vorinostat inhibits STS tumour growth, an effect ameliorated by HIF-2α deletion, implicating HIF-2α as a biomarker for Vorinostat efficacy in STS.

Cite

CITATION STYLE

APA

Nakazawa, M. S., Eisinger-Mathason, T. S. K., Sadri, N., Ochocki, J. D., Gade, T. P. F., Amin, R. K., & Simon, M. C. (2016). Epigenetic re-expression of HIF-2α suppresses soft tissue sarcoma growth. Nature Communications, 7. https://doi.org/10.1038/ncomms10539

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free